Evidence map›Paper›PMID 39534384›Full record

ArticleHemaSphere2024

Causes of death among patients diagnosed with chronic lymphocytic leukemia: A population-based study in the Netherlands, 1996-2020.

Lina van der Straten, Mark-David Levin, Manette A W Dinnessen, Otto Visser, Eduardus F M Posthuma, Jeanette K Doorduijn, Anton W Langerak, Arnon P Kater, Avinash G Dinmohamed

Abstract read
In one paragraph

Article in HemaSphere, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lina van der StratenDepartment of Research and Development Netherlands Comprehensive Cancer Organisation (IKNL) Utrecht The Netherlands.ORCID 0000-0002-9359-1203
Mark-David LevinDepartment of Internal Medicine Albert Schweitzer Hospital Dordrecht The Netherlands.
Manette A W DinnessenDepartment of Research and Development Netherlands Comprehensive Cancer Organisation (IKNL) Utrecht The Netherlands.
Otto VisserDepartment of Registration Netherlands Comprehensive Cancer Organisation (IKNL) Utrecht The Netherlands.
Eduardus F M PosthumaDepartment of Internal Medicine Reinier The Graaf Hospital Delft The Netherlands.
Jeanette K DoorduijnDepartment of Hematology University Medical Center Rotterdam, Erasmus MC Cancer Institute Rotterdam The Netherlands.
Anton W LangerakDepartment of Immunology Erasmus MC Rotterdam The Netherlands.
Arnon P KaterDepartment of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam UMC University of Amsterdam Amsterdam The Netherlands.
Avinash G DinmohamedDepartment of Research and Development Netherlands Comprehensive Cancer Organisation (IKNL) Utrecht The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic lymphocytic leukemia (CLL) manifests heterogeneously with varying outcomes. This population-based study examined causes of death (CODs), as registered by the physician who established the death, among 20,588 CLL patients diagnosed in the Netherlands between 1996 and 2020. Utilizing cause-specific flexible parametric survival models, we estimated cause-specific hazard ratios (HRs) and cumulative incidences of death due to CLL, solid malignancies, other hematological malignancies, infections, and other causes. Our findings reveal CLL as the predominant COD, contributing to around 40% of relative mortality, with a declining 5-year death probability from 16.8% in 1996-2002 to 7.6% in 2010-2020. Also, deaths attributed to solid malignancies, other hematological malignancies, and other COD diminished over time, as evidenced by respective HRs (95% confidence interval) of 0.68 (0.60%-0.77%), 0.45 (0.38%-0.53%), and 0.77 (0.66%-0.90%). In summary, our comprehensive, population-based analysis underscores a noticeable reduction in CLL-attributed deaths and other competing causes over the studied period. Nonetheless, CLL is registered as the most prevalent cause of mortality among contemporary diagnosed patients with CLL, emphasizing the continued relevance of CLL-centric clinical strategies and research.

Identifiers

PMID39534384
PMCPMC11555299

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.